Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Exclusion Criteria

• •Pregnant or nursing
• •Have received treatment with an B cell targeted therapy
• •Have received treatment with a biologic investigational agent in the past year
• •Have received intravenous (IV) cyclophosphamide within 180 days of Day 0
• •Have severe lupus kidney disease
• •Have active central nervous system (CNS) lupus
• •Have required management of acute or chronic infections with the past 60 days
• •Have current drug or alcohol abuse or dependence or within the past year
• •Have a historically positive test or test positive at screening for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
• •Have a history of an allergic or anaphylactic reaction to drugs, food, or insects requiring medical intervention